In the laboratory department of the hospital, in vitro diagnostic equipment is the best "aid" for doctors to grasp the condition. Behind this equipment, nearly 40 disciplines such as physics and chemistry are integrated. This also means that enterprises do not have the time and financial resources to deploy the entire industry chain.
This is where the demand for joint innovation of different subjects comes from. The person in charge of Fosun Diagnostics Technology (Shanghai)** proposed an innovative mechanism - "organization micro-forming". Enterprises do not have to pay out of their own pockets to build a R&D team of hundreds of people, and can match the "specialties" of each link from the market to further reduce costs and increase efficiency, and amplify the overall innovation efficiency.
In this context, Baoshan District unveiled the national innovation reform pilot of "building a multi-subject and full-chain innovation consortium". The list of the first batch of innovation consortiums for the record ended yesterday, and the medical device (in vitro diagnosis) innovation consortium led by Fosun Diagnostics is among them, gathering upstream R&D institutions and businesses such as Shanghai University and Taizhou Zecheng Biotechnology, as well as downstream clinical application scenarios such as Wusong Hospital. Next, all parties will jointly promote the construction of a digital, intelligent, chemical, biological, and biological molecular laboratory to meet the clinical testing needs of tertiary hospitals and make up for the shortcomings in this field in the Yangtze River Delta region.
The Medical Device (In Vitro Diagnostics) Innovation Consortium led by Fosun Diagnostics will promote the construction of a digital, intelligent, chemical, biological, and molecular laboratory.
Aim at the frontier, excavate and subdivide the track to explore freely
The innovation consortium has specifically marked the subdivision - in vitro diagnostics. "Don't follow the trend and gather in popular fields, combine your own expertise and resource endowment, and aim at the cutting-edge track. The relevant person in charge of the Science and Technology Commission of Baoshan District explained. Shanghai has a complete range of medical device industry with strong innovation ability, but from the perspective of subdivision track, in vitro diagnostics belongs to a more specific field, the number of industry enterprises is small, but the application prospect is very impressive.
Taking lung cancer as an example, under the current medical methods, only CT and other methods can be used to check whether the postoperative lesions have metastasized. The lab of the future is expected to solve this problem. "Earlier information about the previous lesions can help to choose the best regimen that is less invasive to the patient. ”
The multidisciplinary integration of the laboratory itself is also expected to promote clinical medical innovation. For example, for the data of complex physical examination reports, a case database is established through expert consultation to solve the "headache and foot pain", so that more medical institutions can have skilled "intelligent inspectors" to help early screening, early detection and early detection of diseases.
Innovate partners, improve risk sharing, and benefit sharing
After multiple investigations and tracking, the person in charge of Fosun Diagnostics Technology (Shanghai) and the team selected the partners of the first batch of innovation consortiums. In his words, from business expansion to clinical research needs, everyone can find their own positioning and advantages in the common goal.
Taking Taizhou Ze as an example, the company specializes in the research and development of in vitro diagnostic reagents and instruments, and has accumulated mature experience in subdivided fields. This "innovative partner" can help Fosun Diagnostics "expand" its in vitro device testing services. The two sides hit it off. Fosun Diagnostics is responsible for building an in vitro diagnostic platform, and Taizhou Zecheng is responsible for the detection of thyroid and bone metabolism reagents. The two sides fully dock and share at the system interface and data level. As a result, Fosun Diagnostics can accelerate its R&D progress and seize innovation opportunitiesTaizhou Zecheng can use the advantages of the platform to open up the vast market of the Yangtze River Delta.
The innovation consortium driven by market demand is also conducive to the formation of an innovation mechanism for risk sharing and benefit sharing. Taking the medical device (in vitro diagnostic) innovation consortium as an example, each member unit signs relevant agreements to clarify the major topics to be tackled, the division of tasks, rights and obligations, etc.
Looking at China, there are only relevant guidelines in the field of in vitro diagnostics, which only serve as a reference and guide, and are weak in binding force on enterprises. "By putting forward suggestions and needs, we can make up for the blind spots that may lead to innovation in going it alone, and make standard rules better escort the development of the industry. ”
*: Shanghai Baoshan official WeChat.